Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational Phase 3 trial of avutometinib in a front-line setting for patients with metastatic pancreatic ductal adenocarcinoma (PDAC)

Next Previous
Trial Profile

A registrational Phase 3 trial of avutometinib in a front-line setting for patients with metastatic pancreatic ductal adenocarcinoma (PDAC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avutometinib (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 27 May 2025 New trial record
  • 22 May 2025 According to a Verastem Oncology media release, the Company is now developing plans for a registrational Phase 3 front-line metastatic PDAC trial to begin in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top